Targeting neddylation E2s: a novel therapeutic strategy in cancer

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The neddylation pathway regulates protein activity through posttranslational modification.
• Ubiquitin-conjugating enzyme E2 M (UBE2M) and ubiquitin-conjugating enzyme E2 F (UBE2F) are critical E2 enzymes in this pathway.
• These enzymes require an N-terminal docking peptide and a catalytic core for neural precursor cell-expressed developmentally downregulated 8 (NEDD8) transfer.

Purpose of the Study:

• To review the mechanisms of UBE2M and UBE2F.
• To highlight UBE2M and UBE2F as potential therapeutic targets in cancer treatment.
• To discuss inhibitors targeting the UBE2M-DCN1 interaction.

Main Methods:

• Literature review of neddylation pathway components.
• Analysis of the structural and functional roles of UBE2M and UBE2F.
• Examination of current therapeutic strategies targeting E2 enzymes.

Main Results:

• UBE2M and UBE2F recruit E3 ligases to modify cullin and non-cullin substrates.
• The UBE2M-defective in cullin neddylation protein 1 (DCN1) interaction is a validated target for cancer therapy.
• These enzymes play diverse biological roles, making them attractive targets.

Conclusions:

• UBE2M and UBE2F are crucial for neddylation and protein function.
• Targeting UBE2M and UBE2F presents a viable therapeutic avenue for various cancers.
• Further research into these enzymes could lead to novel cancer treatments.